Login to Your Account

Adocia Shares Fall as Lilly Terminates Diabetes Alliance

By Cormac Sheridan
Staff Writer

Tuesday, July 30, 2013
Shares in Adocia SAS plunged by as much as 45 percent Tuesday on news that Eli Lilly and Co. has pulled out of an alliance to develop an ultra-fast-acting insulin analogue for diabetes based on Adocia's Biochaperone formulation technology.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription